Healthcare Industry News: intraocular lens
News Release - November 19, 2007
Richard A. Meier Named President of Advanced Medical Optics
SANTA ANA, Calif.--(HSMN NewsFeed)--Advanced Medical Optics, Inc. (AMO) (NYSE:EYE ), a global leader in ophthalmic surgical devices and eye care products, has announced that effective today, Richard (Randy) A. Meier, 48, has been named president of the company. He retains his existing chief operating officer title and responsibilities, which include leadership of the company’s eye care and cataract/implant businesses, global customer services and manufacturing operations.The title of president at AMO was previously held by James V. Mazzo, 50, who remains the company’s chairman and chief executive officer.
“Randy has assumed increasingly broad leadership roles since our spin-off in 2002 and, over that time, has played an integral role in the growth and development of our company,” said Mr. Mazzo. “I am confident in his ability to serve as president, continuing to work closely with me and the AMO leadership team to execute our strategy and deliver on our operational and financial goals.”
Mr. Meier joined AMO in 2002 as corporate vice president and chief financial officer. He subsequently held various positions, including executive vice president, operations and president, eye care business. In February 2007, he was named chief operating officer and chief financial officer, a position he held until October 2007, when Michael Lambert, 45, joined the company as chief financial officer.
About Advanced Medical Optics (AMO)
AMO is focused on providing the full range of advanced refractive technologies and support to help eye care professionals deliver optimal vision and lifestyle experiences to patients of all ages. Products in the cataract/implant line include intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. AMO owns or has the rights to such product brands as ReZoom®, Tecnis®, Clariflex®, Sensar®, and Verisyse® IOLs, Sovereign®, Sovereign® Compact and WhiteStar Signature™ phacoemulsification systems with WhiteStar® technology, Healon® viscoelastics, and the Baerveldt® glaucoma shunt. Products in the laser vision correction line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices, and excimer laser vision correction systems and treatment cards. AMO brands in the laser vision correction business include Star S4 IR®, WaveScan Wavefront®, Advanced CustomVue™, IntraLase® and IntraLasik®. Products in the contact lens care line include disinfecting solutions, enzymatic cleaners and lens rewetting drops. Among the eye care product brands the company possesses are COMPLETE®, COMPLETE® Blink-N-Clean®, Consept®F, Consept® 1 Step, Oxysept® 1 Step, UltraCare®, Ultrazyme®, Total Care™ and blink™ branded products. AMO is based in Santa Ana, California, and employs approximately 4,200 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company's Website at www.amo-inc.com.
Forward-Looking Statements
All forward-looking statements in this press release represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous press releases issued by AMO and AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in AMO's 2006 Form 10-K filed in Third Quarter Form 10-Q filed in November 2007. Copies of press releases and additional information about AMO are available at www.amo-inc.com.
Source: Advanced Medical Optics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
